fashion -WSS

fashion

author：focus 2025-10-01 21:34:49 - browse：315

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Top private equity targets in 2023: cardiology, clinical trials, lasers

WSS

BridgeBio heart drug succeeds in pivotal study

Study: Hearing aids may slow cognitive decline in those at risk

Adopting new red light myopia treatments may be short

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Surgery pushed Ben Carson to fame

hotspot

fashion

focus

Medicare proposal to cover medical devices draws a mixed reaction

Biden administration sends mixed signals on US soldier who crossed into North Korea

Continuity nursing helped my family in our darkest PICU moments

BridgeBio heart drug succeeds in pivotal study

ChatGPT in medicine: STAT answers readers' burning questions

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Hollywood unions extend contract negotiations for actors

UK homeowners get some respite as inflation falls by more than anticipated to a 15

Peter Hotez and the public health issue of online harassment

Gene therapy for Afghan refugees’ infant will be fully covered

entertainment

Robert Kennedy Jr.'s presidential campaign attracts GOP

Why you get paid to donate plasma but not blood

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

A single Democrat is willing to weaken Medicare negotiation power

Devoted Health’s losses in Medicare Advantage persist

Twill hunts for pharma partner to market its depression app

hotspot

leisure time

leisure time

hotspot